Trade RLYB stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Rallybio Corporation (RLYB) is trading at US$16.88, up 0.75% today as of Sep 11, 16:00 EDT. The company has a market capitalisation of US$89.38M. Over the past 52 weeks, RLYB has traded between US$3.67 and US$17.57. On Syfe you can trade RLYB with $0 commission and add it to your watchlist.
| Previous close | US$16.75 |
|---|---|
| Market cap | US$89.38M |
| 52-week range | US$3.67 – US$17.57 |
| Volume | 6.54K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Rallybio Corporation
Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.
Year: 2021
Rallybio Agrees to Acquire Avenzo Therapeutics
Jun 1, 12:49 PM · MT Newswires
Rallybio Corporation (RLYB) stock is trading at US$16.88, +0.75% from the previous close of US$16.75.
The market cap for Rallybio Corporation (RLYB) stock is approximately US$89.38M.
The 52-week high for Rallybio Corporation (RLYB) stock is US$17.57.
The 52-week low for Rallybio Corporation (RLYB) stock is US$3.67.
Rallybio Corporation (RLYB) does not currently pay a dividend.
Stay on top of RLYB
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
